Trials / Completed
CompletedNCT04008771
Intravitreal Injection of SeeQ CdSe 655 Alt Nanoparticles for Patients With Degenerative Retinal Diseases
A Phase 1 Safety And Effectiveness Study of Intravitreal Injection of SeeQ CdSe 655 Alt Nanoparticles for Patients With Degenerative Retinal Diseases
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- 2C Tech Corp · Industry
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
This study was a prospective, open label feasibility study conducted at a single clinical site (APEC, Mexico City) to evaluate the safety and preliminary effectiveness of the SeeQ device, with each patient's serving as his/her own contralateral control.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | SeeQ CdSe 655 ALT | SeeQ CdSe 655 Alt is a sterile colloidal solution of coated CdSe nanoparticles in a borate buffer suitable for intraocular injection. |
Timeline
- Start date
- 2014-01-06
- Primary completion
- 2014-12-19
- Completion
- 2014-12-19
- First posted
- 2019-07-05
- Last updated
- 2019-07-05
Locations
1 site across 1 country: Mexico
Source: ClinicalTrials.gov record NCT04008771. Inclusion in this directory is not an endorsement.